Luigi Lorini, Medical Oncologist at Humanitas Research Hospital, shared a post on LinkedIn:
“What’s next for immunotherapy in head and neck cancer? Is PD-L1 CPS evaluation on the primary tumor as reliable as on recurrent/metastatic lesions? Some insights from the CONCORDL-1 study. What are the preliminary insights from the PRIME trial (combining ICI + PARPi as neoadjuvant-adjuvant strategy in locally advanced HNSCC)?
I had the opportunity to share my thoughts on these crucial topics during the latest ESMO meeting in Barcelona.
A big thank you to Video Journal of Oncology (VJOncology) for the invitation and the valuable support!Stay tuned for more updates – the field is evolving fast!
Web link.”
You Can Read Insights from CONCORDL-1 study
More posts featuring Luigi Lorini.